BioSpace News Archive

Kernel, a pioneer in neuroimaging technology, is proud to unveil its groundbreaking Flow2 system, a major leap forward in the field of functional neuroimaging.

Aytu BioPharma, Inc. and Medomie Pharma Ltd, today announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu’s Adzenys XR-ODT® and Cotempla XR-ODT® product lines.

AMIRO (“the Company”), a leading beauty and skincare technology brand, is thrilled to announce that its research facility, AMIRO LAB , has successfully obtained the Qualified Testing Location (QTL) certification after a comprehensive audit conducted by SGS.

Pattern Bioscience, Inc. today announced that it was named the winner of the Disruptive Technology Award from the Association for Diagnostics & Laboratory Medicine (ADLM, formerly known as AACC).

Mustang Bio, Inc. today announced that, on July 28, 2023, it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc.

PharmAla Biotech Holdings Inc. is thrilled that it has filed a patent on the composition of matter of PharmAla-1.

Sera Prognostics Inc. today announced that it will report second quarter fiscal year 2023 financial results on Wednesday, August 9, 2023, after the close of the market.

Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, announced the publication of a first-in-human study featuring the FreeClimb® 70 reperfusion system in the Interventional Neuroradiology Journal.

AnaptysBio, Inc. (Nasdaq: ANAB) today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.

The Society for Vascular Surgery, the leading medical organization dedicated to advancing quality in vascular health care, has issued a response to a recent New York Times article detailing allegations of overuse of interventions to treat patients with peripheral vascular disease.